165 related articles for article (PubMed ID: 36661721)
21. Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer.
Osumi H; Shinozaki E; Suenaga M; Wakatsuki T; Nakayama I; Matsushima T; Ogura M; Ichimura T; Takahari D; Chin K; Nagasaki T; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Yamaguchi K
PLoS One; 2017; 12(5):e0176745. PubMed ID: 28562679
[TBL] [Abstract][Full Text] [Related]
22. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.
Oh SE; An JY; Choi MG; Lee JH; Sohn TS; Bae JM
Technol Cancer Res Treat; 2021; 20():15330338211039679. PubMed ID: 34605706
[No Abstract] [Full Text] [Related]
24. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
[TBL] [Abstract][Full Text] [Related]
26. The role of adjuvant chemotherapy in stage II colorectal cancer patients.
Lin HH; Chang YY; Lin JK; Jiang JK; Lin CC; Lan YT; Yang SH; Wang HS; Chen WS; Lin TC; Chang SC
Int J Colorectal Dis; 2014 Oct; 29(10):1237-43. PubMed ID: 25024041
[TBL] [Abstract][Full Text] [Related]
27. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.
Sun J; Ilich AI; Kim CA; Chu MP; Wong GG; Ghosh S; Danilak M; Mulder KE; Spratlin JL; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2016 Sep; 15(3):257-63. PubMed ID: 26803708
[TBL] [Abstract][Full Text] [Related]
28. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
Zhang Q; Qian Y; Yin Y
Eur J Clin Pharmacol; 2021 Dec; 77(12):1791-1804. PubMed ID: 34275019
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study.
Kitazume Y; Kawazoe H; Uozumi R; Yoshizawa T; Iihara H; Fujii H; Takahashi M; Arai T; Murachi Y; Sato Y; Mikami T; Hashiguchi K; Yamazaki T; Takahashi K; Fujita Y; Hosokawa Y; Morozumi I; Tsuchiya M; Yokoyama A; Hashimoto H; Yamaguchi M
Sci Rep; 2022 Apr; 12(1):6561. PubMed ID: 35449143
[TBL] [Abstract][Full Text] [Related]
30. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
[TBL] [Abstract][Full Text] [Related]
32. Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II - III elderly patients with colon cancer.
Park J; Baik H; Kang SH; Seo SH; Kim KH; Oh MK; Lee HS; Lee SH; Kim KH; An MS
Asian J Surg; 2022 Jan; 45(1):448-455. PubMed ID: 34364765
[TBL] [Abstract][Full Text] [Related]
33. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
34. Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan.
Minami K; Morita M; Emi Y; Okamoto M; Tanaka E; Nagata S; Touyama T; Ohgaki K; Tanaka T; Okumura H; Suenaga T; Tokunaga S; Oki E; Kakeji Y; Akagi Y; Baba H; Natsugoe S; Maehara Y;
Int J Clin Oncol; 2017 Jun; 22(3):505-510. PubMed ID: 28101757
[TBL] [Abstract][Full Text] [Related]
35. [Clinical study on survival benefit for elderly patients with resected stage II or III colorectal cancer based on traditional Chinese medicine syndrome differentiation and treatment].
Tao L; Zhu YJ; Lu XM; Gu Y; Zhao AG; Zheng J; Fu CG; Yang JK
Zhong Xi Yi Jie He Xue Bao; 2010 Dec; 8(12):1159-64. PubMed ID: 21144459
[TBL] [Abstract][Full Text] [Related]
36. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
37. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
38. Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer.
Akabane S; Shimizu W; Takakura Y; Kochi M; Taguchi K; Nakashima I; Sato K; Hattori M; Egi H; Sentani K; Yasui W; Ohdan H
Int J Clin Oncol; 2021 Jul; 26(7):1285-1292. PubMed ID: 33881678
[TBL] [Abstract][Full Text] [Related]
39. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y
BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
Park SH; Lim DH; Sohn TS; Lee J; Zang DY; Kim ST; Kang JH; Oh SY; Hwang IG; Ji JH; Shin DB; Yu JI; Kim KM; An JY; Choi MG; Lee JH; Kim S; Hong JY; Park JO; Park YS; Lim HY; Bae JM; Kang WK;
Ann Oncol; 2021 Mar; 32(3):368-374. PubMed ID: 33278599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
